Evidence and regulation for COVID-19 self-tests

Vigil Sanit Debate, Rio de Janeiro, 2023, v.11: e02063 | Published on: 27/02/2023

Authors

  • Erika Programa de Evidências para Políticas e Tecnologias em Saúde, Gerência Regional de Brasília, Fundação Oswaldo Cruz (Fiocruz), Brasília, DF, Brasil Author https://orcid.org/0000-0003-1482-8282
  • Maíra Catharina Ramos Programa de Evidências para Políticas e Tecnologias em Saúde, Gerência Regional de Brasília, Fundação Oswaldo Cruz (Fiocruz), Brasília, DF, Brasil Author https://orcid.org/0000-0003-3829-975X
  • Flávia Programa de Evidências para Políticas e Tecnologias em Saúde, Gerência Regional de Brasília, Fundação Oswaldo Cruz (Fiocruz), Brasília, DF, Brasil Author https://orcid.org/0000-0002-7142-6266

DOI:

https://doi.org/10.22239/2317-269x.02063

Keywords:

COVID-19, SARS-CoV-2, Self-testing, Home Based Testing, Regulation

Abstract

Introduction: The development of new diagnostic tests for SARS-CoV-2 is a strategic component for the prevention and control of COVID-19. To regulate the market for SARSCoV-2 antigen detection self-tests, the regulatory agency issued a resolution that provided for the introduction of self-tests in Brazil. Objective: To perform a comparison between the
new technical requirements of antigen self-tests for COVID-19 with data and information available in the literature. Method: This is a systematic literature review to carry out a comparative study between the scientific evidence and the new technical requirements for the commercialization of antigen self-tests for COVID-19 in Brazil. The search was performed in October 2021, and updated in January 2022. Results: Of the 517 studies identified, nine were included. The studies reported adequate sensitivity and specificity results for most self-tests performed in symptomatic people. The studies bring a variety of tests available and one of them was registered for commercialization in Brazil. Based on this outcome, national regulation follows standards that favor the promotion of self-monitoring by the population, which can contribute to a public health policy. Conclusions: The technical requirements contained in the new regulation and at the national level are consistent with the evidence found, which ensures reliability for decision-making by consumers, clinicians and service providers. It is necessary to continue with studies on self-test coverage for new variants, biological material disposal policies and how the use of self-tests can contribute to the role of consumers in health surveillance actions.

Downloads

Download data is not yet available.

Author Biographies

  • Erika, Programa de Evidências para Políticas e Tecnologias em Saúde, Gerência Regional de Brasília, Fundação Oswaldo Cruz (Fiocruz), Brasília, DF, Brasil
  • Maíra Catharina Ramos, Programa de Evidências para Políticas e Tecnologias em Saúde, Gerência Regional de Brasília, Fundação Oswaldo Cruz (Fiocruz), Brasília, DF, Brasil
  • Flávia, Programa de Evidências para Políticas e Tecnologias em Saúde, Gerência Regional de Brasília, Fundação Oswaldo Cruz (Fiocruz), Brasília, DF, Brasil

Published

2023-02-27

Issue

Section

Revision article

How to Cite

Evidence and regulation for COVID-19 self-tests: Vigil Sanit Debate, Rio de Janeiro, 2023, v.11: e02063 | Published on: 27/02/2023. (2023). Health Surveillance under Debate: Society, Science & Technology , 11, 1-9. https://doi.org/10.22239/2317-269x.02063

Most read articles by the same author(s)